Research institution
Institut Paoli-Calmettes Clinical Trials
Studies where Institut Paoli-Calmettes is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 43Breast Cancers, Ovarian Cancers
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
- Trial name
- GENEPSO (NCT03667417)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Institut Paoli-Calmettes
Kidney Cancer
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
In the current era of immune checkpoint inhibitors (ICI), the role and timing of nephrectomy remains unknown, particularly in cases of residual kidney disease after a major response at metastatic sites.
- Trial name
- NAMECAR (NCT06882486)
- Testing
- nephrectomy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Paoli-Calmettes
Solid and Hematologic Cancer
Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission
This is a single-center, non-randomized feasibility study. For this study, 19 young adults treated for cancer at the Paoli-Calmettes Institute will be included.This study includes interviews and questionnaires to assess the…
- Trial name
- rebond-jas (NCT07861971)
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Institut Paoli-Calmettes
Early Triple-Negative Breast Cancer
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
This multicenter phase II study evaluates a de-escalation strategy of neoadjuvant chemo-immunotherapy in patients with stage II early triple-negative breast cancer and tumor-infiltrating lymphocytes (TILs) ≥ 30%.
- Trial name
- DECREASE (NCT07857486)
- Testing
- Pembrolizumab
- Volunteers
- 84 people
- Sponsor
- Institut Paoli-Calmettes
Colonic Cancer
Butyrophilins Role in Colon Cancer
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
- Trial name
- IMMUNOCOL (NCT04185272)
- Testing
- analysis of BTN and BTNL status
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Cancer Of Pancreas
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor.
- Trial name
- GemSign-01 (NCT06046794)
- Testing
- Analyze of GemCore status
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Cancer
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
The goal of this observational study is to develop and validate a preoperative immunological signature for predicting postoperative pancreatic fistula (POPF) in adult patients undergoing pancreatic surgery for pancreatic cancer.
- Trial name
- NCT07827911
- Testing
- blood sampling
- Where
- France
- Volunteers
- 310 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Adenocarcinoma Metastatic
Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating…
- Trial name
- NCT07664891
- Testing
- Biopsy collection, Blood collection
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Institut Paoli-Calmettes
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia
FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) predominantly affect older adults, and their incidence continues to rise with advanced age.
- Trial name
- FT-RIC-HAPLO (NCT07598110)
- Testing
- fludarabine and treosulfan
- Volunteers
- 77 people
- Sponsor
- Institut Paoli-Calmettes